- Molecular NameEnalapril
- SynonymEnalapril Maleate; Enalaprila [INN-Spanish]; Enalaprilat; Enalaprilum [INN-Latin]
- Weight348.399
- Drugbank_IDDB00584
- ACS_NO75847-73-3
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)-1.25
- pka2.97 and 5.35
- LogD (pH=7, predicted)-2.3
- Solubility (experiment)25 mg/mL
- LogS (predicted, ACD/Labs)(ph=7)0.46
- LogSw (predicted, AB/LogsW2.0)25.37
- Sw (mg/ml) (predicted, ACD/Labs)19.96
- No.of HBond Donors3
- No.of HBond Acceptors7
- No.of Rotatable Bonds8
- TPSA106.94
- StatusFDA approved
- AdministrationI.V. and P.O.
- PharmacologyAn angiotensin converting enzyme (ACE) inhibitor used in the treatment of hypertension and some types of chronic heart failure.
- Absorption_value63.0
- Absorption (description)After oral administration, 60% of a dose is absorbed
- Caco_2-5.64
- Bioavailability41.0
- Protein binding55.0
- Volume of distribution (VD)1.7 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmRapidly and extensively hydrolysed in the liver to enalaprilat. Peak plasma concentrations of enalaprilat are achieved 3 to 4 h after oral dose.
- Half life11 h
- ExcretionEnalapril is excreted in urine as the metabolite, enalaprilat, and the rest in faeces as the unchanged drug. After a single oral dose of 20 mg enalapril, enalapril and enalaprilat can be detected in breast milk with a concentration of 1 to 2.3 μg/L for the latter. Enalaprilat is removed by haemodialysis and peritoneal dialysis.
- Urinary Excretion88
- Clerance4.9 ml/min/kg
- ToxicityTreatment with enalapril can result in renal failure, with the possibility of death. Severe hypotension is the main toxic effect and loss of hearing has also been reported by some.
- LD50 (rat)N/A
- LD50 (mouse)N/A